[dropcap]W[/dropcap]elcome to a new year on Oncology Central! As 2017 gets off to a busy start, we’re taking this opportunity to look back at 2016 on Oncology Central, and to review some of the topics and data within oncology that really got you talking over the course of the last year.
Unsurprisingly, one of the key oncology themes over the last year has been the continued coming of age of cancer immunotherapy, with promising new data having been presented at every major oncology meeting since the modality was hailed clinical cancer advance of the year by ASCO back in February 2016. As President of ASCO, Julie M Vose suggested at the time: “No recent cancer advance has been more transformative than immunotherapy. These new therapies are not only transforming patient lives, they are also opening intriguing avenues for further research.”
As touched on above, there has also been a lot of breast cancer-related content that you, our audience, have really engaged with within the last year. Did you read our featured meta-analysis article from Biomarkers in Medicine discussing potential prognostic biomarkers in triple-negative disease? Our interview with expert Richard Simcock discussing single-dose intraoperative radiotherapy for early stage breast cancer also proved to be one of our most read item of the year. In case you missed it, discover how single-dose intraoperative radiotherapy compares with daily external beam radiotherapy and explore clinical data that reported positive patient experience outcomes.
At the 2016 ASCO meeting, data presented by Venook et al observed that metastatic colorectal cancer patients had different treatment outcomes based on the location of their tumor, adding fuel to the debate over whether tumor location could represent a prognostic or predictive marker in the disease.
We explored this further in a series of interviews with key experts in the field, beginning with Professor Julien Taieb discussing whether these data could impact the way physicians select treatment for their patients. Furthermore, Professor Claus-Henning Köhne explained the data further in the context of broader evidence on biomarkers in metastatic colorectal cancer and current recommendations for patients.